

**CNS Pharmaceuticals, Inc.**  
**2100 West Loop South, Suite 900**  
**Houston, TX 77027**

February 1, 2021

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporate Finance  
Washington, DC 20549

**Re: CNS Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3**  
**File No. 333-252471**

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on February 3, 2021, or as soon thereafter as possible on such date.

Very truly yours,

**CNS Pharmaceuticals, Inc.**

By: /s/ Christopher Downs  
Name: Christopher Downs  
Title: Chief Financial Officer